Analysis of associations of NAT2 gene polymorphisms with the risk of lung cancer

Bulletin of Experimental Biology and Medicine

Volumn 143, Issue 1, 2007, Pages 83-86

  Nikishina, M V ^a   Vavilin, V A ^a   Makarova, S I ^a   Lyakhovich, V V ^a  

^a INSTITUTE OF MOLECULAR BIOLOGY AND BIOPHYSICS   (Russian Federation)

Author keywords

Case controlstudy; Genetic polymorphism; Lung cancer; NAT2; Tobacco smoking

Indexed keywords

ARYLAMINE ACETYLTRANSFERASE;

ADULT; ARTICLE; CANCER RESISTANCE; CANCER RISK; CAUCASIAN; CONTROLLED STUDY; FEMALE; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; HUMAN; HUMAN CELL; INCIDENCE; LUNG CANCER; MAJOR CLINICAL STUDY; MALE; RUSSIAN FEDERATION; SMOKING;

ARYLAMINE N-ACETYLTRANSFERASE; CASE-CONTROL STUDIES; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; GENETIC PREDISPOSITION TO DISEASE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; POLYMORPHISM, GENETIC; RISK; SIBERIA; SMOKING;

NICOTIANA TABACUM;

EID: 34249111685     PISSN: 00074888     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10517-007-0023-0     Document Type: Article

References (9)

1. M. V. Nikishina, A. G. Akishev, S. I. Makarova, et al., Biomed. Khim., 50, No. 3, 269-272 (2004).
2. J. Borlak and S. M. Reamon-Buettner, BMC Med. Genet., 7, 58 (2006).
3. A. J. Fretland, M. A. Leff, M. A. Doll, and D. W. Hein, Pharmacogenetics, 11, No. 3, 207-215 (2001).
4. D. W. Hein, Toxicol. Lett., 112-113, 349-356 (2000).
5. D. W. Hein, D. M. Grant, and E. Sim, Pharmacogenetics, 10, No. 4, 291-292 (2000).
6. D. Hickman, J. R. Palamanda, J. D. Unadkat, and E. Sim, Biochem. Pharmacol., 50, No. 5, 697-703 (1995).
7. D. Hickman, A. Risch, J. P. Camilleri, and E. Sim, Pharmacogenetics, 2, No. 5, 217-226 (1992).
8. D. Hickman and E. Sim, Biochem. Pharmacol., 42, No. 5, 1007-1014 (1991).
9. U. A. Meyer and U. M. Zanger, Annu. Rev. Pharmacol Toxicol., 37, 269-296 (1997).